Clinical Trial Update: Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the non-inferiority of cefoxitin versus imipenem/cilastatin for urinary tract infections caused by ESBL-producing Escherichia coli ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urinary Tract Infections

Drugs mentioned

• Cefoxitin (Cefoxitin)
• Imipenem/Cilastatin (imipenem/cilastatin)

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Urinary Tract Infections | Phase 4 | Status: TERMINATED